Anti NMDAR autoimmune encephalitis: associated cancers
Evidence-based neurology checklist on anti nmdar autoimmune encephalitis: associated cancers: Demographic features Tumours occur in 20-59% of cases Detection may require long term annual tumour screening Tumour types Predictors of malignancy
Demographic features
- Tumours occur in 20-59% of cases
- Detection may require long term annual tumour screening
Tumour types
Predictors of malignancy
References
- Kümpfel T, Gerdes LA, Heck C, Prüss H. Delayed diagnosis of extraovarian teratoma in relapsing anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflamm 2016; 3:e250.
- Dalmau J, Glelchman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case serious and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091-1098.
Related checklists
- Anti NMDAR autoimmune encephalitis: clinical features
- Anti NMDAR autoimmune encephalitis: atypical features
- Anti NMDAR autoimmune encephalitis: differential diagnosis
- Anti NMDAR autoimmune encephalitis: outcomes
- Anti NMDAR autoimmune encephalitis: investigations
- Anti NMDAR autoimmune encephalitis: treatment